QUÉBEC, June 2, 2014 /CNW Telbec/ - After several requests for
reimbursement, the Centre and Association for People Living with
Hepatitis C (CAPAHC) was elated when the Régie de l'assurance maladie
du Québec (RAMQ) announced today that it will add Sovaldi to the list
of reimbursed medications. Patients suffering from hepatitis C
genotypes 1 and 4 can now use this medicine at any stage of the disease
(regardless of the level of fibrosis). This is a significant milestone
for hepatitis C patients, who can now benefit from a shorter and more
efficient treatment, with fewer side effects.
"Wonderful news! On behalf of the 50,000 patients suffering from
hepatitis C in Québec and those who will contract it in the coming
years, I thank the Québec government for giving hope to our patients
and enhancing the quality of their lives," said CAPAHC President
Recently, the Canadian Liver Foundation (CLF) made public a new study
showing a significant rise in common health complications associated
with hepatitis C over the next 20 years, which would drive up
healthcare costs by 60% by 2032. The number of Canadians suffering from
chronic hepatitis C with cirrhosis and more advanced liver disease is
expected to rise to 23% by 2035 from 8.7% in 2013. As a result of the
increasing progression of the disease in Canada, it is estimated that
there will be a 205% increase in the cases of liver cancer and a 160%
increase in the cases of liver disease-related deaths.
Founded in 2003, CAPAHC provides support to people infected or affected
by Hepatitis C, people co-infected with HIV/HCV, and their loved ones.
It promotes overall health through prevention and understanding of the
Hepatitis C virus and other related illnesses to its community without
discrimination. CAPAHC also designs and implements information,
awareness and educational programs.
SOURCE: Centre and Association for People Living with Hepatitis C (CAPAHC)
For further information: